Antibodies of the IgG class carry a pair of oligosaccharides (N-glycans) in the Fc region. The importance of the N-glycan is clearly demonstrated by its profound effect in the physicochemical and biological properties of antibodies. The term 'glycoengineering' has been coined to describe contemporary strategies to improve the performance of therapeutic monoclonal antibodies on the basis of modifications in the structure and composition of the N-glycan. These methodologies have resulted in the approval and commercialization of a new generation of antibodies with improved therapeutic efficacy. So far, these advances have been driven by herculean efforts in a process of trial-and-error. The collective work of researchers in this field is progressively revealing the molecular basis of N-glycans for the function of antibodies. This knowledge will ultimately be conducive to the application of rational approaches for the successful manipulation of antibodies using glycoengineering strategies. Herein, we review advances in our understanding of the role of the N-glycan in the structural and dynamic integrity, and biological activity, of antibodies. Since the N-glycan has a multifaceted effect in antibodies, in this review we have emphasized the importance of integrating various techniques that address this problem from multiple points of view. In particular, the combination of X-ray crystallography with nuclear magnetic resonance, molecular dynamics simulations and biophysical approaches based on thermodynamic principles, has emerged as a powerful combination that is deepened our understanding of this unique system with critical implications for human well-being.
Introduction
IgG carries an N-glycan attached to each Asn297 residue of the IgG-Fc modulating its biological function (1) . The N-glycan contains an invariable core structure composed of four N-acetylglucosamine (GlcNAc) and three mannose (Man) moieties, and additional monosaccharides not always present such as fucose (Fuc), galactose (Gal), bisecting GlcNAc and sialic acid N-acetylneuraminic acid (Neu5Ac) or N-glycolylneuraminic acid (Neu5Gc) (Fig. 1) . N-glycans can thus appear in multiple configurations and compositions, leading to >400 different variants when pairing the two CH2 domains of IgG-Fc (2) . It is clear that the N-glycan moiety attached to IgG-Fc exhibits a great diversity and remarkable heterogeneity, each configuration potentially affecting the effector functions of therapeutic antibodies in a slightly different manner.
It is widely accepted that the N-glycan has a multifaceted impact on the stability, conformation, aggregation, and effector function of therapeutic antibodies (3) (4) (5) (6) . Moreover, the N-glycan footprint of serum antibodies differs between healthy individuals and patients suffering from rheumatic diseases, although the reasons for that have not been clarified so far (7, 8) . A long-term goal is to rationalize the impact of glycosylation in the various effector functions, such as antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cell-mediated phagocytosis (ADCP) or complement-dependent cytotoxicity (CDC), all of them vigorously studied in connection with human disease (3) . Those cytotoxic effects are triggered upon formation of antibodyantigen complexes, also known as immune complexes. Subsequently, the immune complexes are recognized by Fcγ receptors (FcγRs), anchored in the plasma membrane of specialized immune cells, and/or by the complement system.
The magnitude of the immune response depends largely on the binding affinity of IgG-Fc to its cellular FcγRs (9) . Since the amino acid sequence influences the properties of proteins, mutagenesis in the IgG-Fc region has been an attractive strategy to drastically enhance (or inhibit) not only the thermal stability or serum half-life, but also the effector function (ADCC, ADCP and CDC) of therapeutic antibodies (10) (11) (12) . In addition, it is increasingly accepted that the conformational ensemble of the Fc region fine-tunes and modulates the recognition of receptors (13) (14) (15) . Indeed, changes in the composition of the N-glycan influences the conformation of IgG-Fc, leading to alterations in the binding affinity for FcγRs (16) . It is thus clear that a comprehensive understanding of the effect of glycosylation in the conformational landscape of IgG-Fc is required to precisely modulate the effector functions of therapeutic antibodies. This strategy has been validated by the first wave of glycoengineered antibodies yielding more effective therapeutic outcomes (17, 18) .
A large number of X-ray crystal structures of IgG-Fc and its mutants are reported in the literature and in the Protein Data Bank (PDB), establishing the molecular basis for interaction between IgG-Fc and its receptors (13, 19) . The collective evidence indicates that IgG-Fc displays a significant structural heterogeneity, even in the crystalline state. It is thus clear that IgG-Fc has an intrinsic conformational variability; in this review, we discuss mechanisms by which glycosylation influences the conformational ensemble and its expected impact in the function of the antibody. We distinguish three types of phenomena: (i) the open/closed conformation of IgG-Fc, (ii) the local perturbation of key residues for the interaction and (iii) the fluctuation of the N-glycan itself. In addition, we discuss in some detail two particular aspects of the N-glycan, namely the special role of the fucose moiety in the effector function, and the influence of glycosylation in the unfolding, aggregation and thermal stability of IgG.
The open/closed conformation of IgG-Fc
The impact of glycosylation on the open/closed conformation of IgG-Fc has been examined on several reports, although a consensus model has yet to be agreed among the researchers (15, (19) (20) (21) . These studies demonstrated different degrees of aperture of the CH2 domains of IgG-Fc in different crystal structures (Fig. 2) . For example, the distance between residue Pro238 in one chain of CH2 and Pro238 of the second chain of CH2 varies by up to 25 Å (a minimum distance of 11 Å and a maximum distance of 36 Å was reported) (15) . Similarly, the range of distances observed between other pairs of residues such as Phe241 (17-33 Å), Arg301 (26-47 Å) or Pro329 (19-41 Å) is also remarkably broad.
However, there is no clear correlation between the distances between CH2 domains and parameters of the crystal lattice such as maximum resolution, space group or crystal packing regions. Similarly, no definite relationship between the aperture of the CH2 domains and the glycosylation status of IgG-Fc was observed. Two examples in which IgG-Fc exhibits small deviations have been described when wild type is compared to glycoengineered IgG-Fc (15) or when IgG-Fc is analyzed bound to FcγRs (22) .
In parallel, the open/closed form of IgG-Fc has also been studied using molecular dynamics (MD) simulations, a class of computer simulations that yields valuable conformational information at short timescales otherwise difficult to obtain from experimental methodologies. The computational analysis reveals considerable heterogeneity of the CH2 domains (20) in agreement with the crystallographic data. The CH2/ CH3 dihedral angle ranged from −49° to +5°, leading to variations of the distance between CH2 domains at position Asn297 ranging from 24 to 37 Å. Buck et al. (23) performed MD simulations using a glycosylated (G2F), a partly deglycosylated (M3N2) and an aglycosylated form of IgG-Fc; the initial coordinates for the simulations were obtained from the PDB. This study reported that fluctuations of increasing amplitude in CH2 were correlated with the degree of deglycosylation of IgG-Fc.
The glycan-glycan interactions at the interface between the two CH2 domains thus influence the dynamic behavior of the CH2 domain itself. Additional evidence is provided by sedimentation coefficients analysis. It was determined that disrupting the glycan-glycan interaction induces increased hydrodynamic volume, suggestive of a relaxed conformation (6) . These glycan-glycan interactions have been classified into three groups according to the number of hydrogen bonds (H-bonds) between Man moieties at the α1-3 arm of each chain: no interaction, one H-bond and two H-bonds (24) .
Fluctuation of loops
Although the crystal structure of a protein represents the average coordinates of atoms in a three-dimensional lattice, it is possible to evaluate the dynamic behavior of the molecules from the so-called B-factors (temperature factors), where greater B-factors represent a more dynamic state. As reported by several groups, the distribution of B-factors indicates clear asymmetric features of the two CH2 domains of IgG-Fc (Fig. 3) (13, 14, 22) . One of the CH2 domains displays, in most cases, a more dynamic behavior than the other CH2 domain as judged from the B-factors, a perplexing observation given that IgG is a homodimer (i.e. a molecule composed of two identical protein monomers). Crystal lattice contacts alone cannot explain this phenomenon, since the asymmetry is observed in crystal structures that were determined in different space groups, and even in one example no signs of asymmetric features are found.
In a pioneering study, Krapp et al. (19) discovered a correlation between the length of the N-glycan and the magnitude of the B-factor. The authors reported that the longer the N-glycan, the lower the B-factor in the CH2 domain, suggesting that the dynamic features are favored in cases where some degree of deglycosylation had occurred.
Nuclear magnetic resonance (NMR) is a spectroscopic technique perfectly suited to address some of these questions at the atomic level. In NMR, examining the magnetic properties of isotopes such as 1 H and 15 N yields a dynamic portrait of the molecule under analysis. In a landmark study, Yamaguchi et al. (25) determined the residues perturbed in CH2 after trimming the terminal saccharide units of the N-glycans. The 1 H-15 N heteronuclear single quantum coherence spectra revealed an increasingly larger number of residues affected by the step-wise cleavage of the N-glycan. These data demonstrated that a large number of residues are interacting with the N-glycan moiety in a significant way, as it was expected from the large contact area between the CH2 domain and the N-glycan observed in the crystal structures.
The effect of glycosylation in the fluctuations of the protein has been recently examined in detail by the group of Barb (26) (27) (28) . Using NMR, these researchers compared the data of native IgG-Fc with that of the deglycosylated molecule, finding that the effect of glycosylation on the orientation of CH2 is restricted to small amplitudes. The authors concluded that the N-glycan stabilizes the C′E loop where Asn297 sits (Fig. 4) by means of non-covalent interactions. These interactions reduce the fluctuation of glycan and protein, helping to pre-organize the interaction surface with the receptor FcγRIIIa. This is an important observation that directly links the affinity of IgG-Fc for FcγRIIIa, and the composition of the N-glycan, evoking an allosteric mechanism not requiring direct contact between the terminal saccharides of the N-glycan and FcγRIIIa receptor.
Houde et al. (29) reported the impact of glycosylation on antibody conformation using hydrogen-exchange mass spectrometry (HDX MS), a powerful methodology to measure local backbone dynamics of proteins in solution (30) . The authors generated native, deglycosylated, degalactosylated, hypergalactosylated, methionine-oxidized and methionineoxidized-hypergalactosylated antibodies by treatment with enzymes, chemical modifications or both. They identified 
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a segment of the CH2 domain-241 FLFPPKPKDTLMI 253 -located at the interface adjacent to the N-glycan and in the vicinity of the CH3 domain showing a high uptake of deuterium as the glycosylation level decreased. In the crystal structures, the two Phe residues of this segment are contacting the N-glycan (Fig. 4) , demonstrating the importance of these non-covalent interactions to stabilize the IgG-Fc region of the antibody. This mechanism has been recently confirmed by site-directed mutagenesis of these and neighboring residues (27, 31) .
N-glycan dynamics
The motion of the terminal saccharides of the N-glycan is certainly another aspect to consider when explaining the influence of the N-glycan on IgG-Fc at the molecular level. The α1-3 arm of the N-glycan is not as well resolved, as that of the α1-6 arm, in crystallographic studies (see Fig. 4 for an indication of the two arms). This observation is explained by the higher flexibility of the α1-3 arm and quantified by greater B-factors and a broader dihedral angle distribution (24) , which is the consequence of its higher exposure to solvent (i.e. less contact with the protein surface) (15, 19) . On the contrary, saccharides belonging to the α1-6 arm strongly interact with Phe243, explaining the restricted mobility (24) . Solution NMR supports this view, indicating that the α1-6 arm remains immobilized on the surface of the CH2 domain, whereas the α1-3 arm fluctuates between the solvent and the protein surface (32, 33) .
More elaborate and detailed studies by NMR have recently shown the fine-dynamics of the α1-6 arm, but without questioning the greater mobility of the solvent-exposed α1-3 arm (26, 34, 35) . These studies indicated that the α1-6 arm experiences two different chemical environments. In parallel, Frank et al. (20) examined this problem by MD simulations. They reported that one conformation corresponds to the 'bound' form in which the α1-6 arm is contacting the CH2 domain. In contrast, in the second conformation, the α1-6 branch is partially detached from the protein surface, leading to a state of elevated motion. The computational analysis estimates that C1 of Gal is positioned <9 Å from the Cα of Pro244 in the so-called bound state, but increases to >9 Å in the detached stated. Concomitantly, the ω torsion angle of the α1-6 Man shifts from 180° to −60°. These results are consistent with the two-state model described by NMR (34, 35) .
A remarkable crystal structure of the humanized therapeutic antibody pembrolizumab has open a new debate about the conformation of the CH2 domain and the exposure of the N-glycan attached to it (36) . Pembrolizumab is an antibody of the IgG4 subclass approved for the treatment of melanoma and is composed of the complementary-determining regions of a mouse anti-human PD-1 antibody in frameworks of human variable regions fused with the constant regions of a human IgG4 molecule (36) , and containing the mutation Ser228Pro in the hinge region to minimize the phenomenon of Fab-arm exchange (37, 38) . In the crystal structure, it is shown that the CH2 domain adopts two remarkably distinct orientations, each with a different degree of solvent exposure (Fig. 5) . Although these two conformations could in principle explain the two-state model observed by NMR, it will be first necessary to corroborate if the relative position of CH2 in the crystal structure is forced by packing artifacts and/or influenced by the mutation Ser228Pro, or on the contrary represents a bona fide conformation of the antibody in solution.
Direct effect of fucose on ADCC activity
A significant effort has been devoted to understand the impact of the fucose present in the N-glycan (Fig. 1) in the effector function of antibodies. The importance of this fucose stems from the observation that, in its absence, the ADCC activity increases dramatically (39, 40) although no structural changes of IgG-Fc are associated with its presence or absence (41) . For example, Shields et al. revealed that afucosylated anti-HER2 antibody exhibits an ~100-fold greater ADCC effect with respect to the fucosylated counterpart (39) (anti-HER2 is a therapeutic antibody for the treatment of breast cancer). Precisely, the production of afucosylated antibodies is the key strategy underlying the first two examples of glycoengineered therapeutic antibodies approved for human therapies. Mogamulizumab was approved in 2012 for patients with relapsed or refractory CCR4-positive adult cell leukemia-lymphoma (17, 42) , whereas obinutuzumab is an anti-CD20 antibody indicated for patients with chronic lymphocytic leukemia and co-existing conditions (18) .
To understand the fundamental principles explaining the dramatic effect of fucosylation on ADCC, biophysical studies using high-resolution calorimetric techniques were conducted. It was shown that the afucosylated antibody binds to the FcγRIIIa receptor with higher affinity than the fucosylated version does (31-21-fold). The enhanced affinity is achieved by engaging in additional non-covalent interactions (enthalpy-driven) (43) . However, because the crystal structures clearly showed that the fucose moiety does not modify the structure of IgG-Fc or cannot interact directly with the polypeptide chain of FcγRIIIa (44), the molecular mechanism remained elusive for a long time.
Ferrara et al. (45) reported that the differences in affinity between the fucosylated and afucosylated antibody happen only if the N-glycan attached to Asn162 of the receptor FcγRIIIa is also present. Glycosylation of Asn162 significantly enhances the relative affinity of the afucosylated antibody with respect to the fucosylated version, whereas glycosylation of FcγRIIIa at other residues had little influence on the fucose-dependent discrimination (46) .
Almost simultaneously, Ferrara et al. (47) and Mizushima et al. (48) demonstrated that the fucose moiety clashes with saccharide units of the N-glycan of the receptor FcγRIIIa, thus imposing steric hindrance and thereby explaining the unfavorable interaction in the fucosylated state (Fig. 4b) . This explanation is consistent with previous data showing that the N-glycan of FcγRIIIa is compatible with the afucosylated N-glycan of IgG-Fc (45, 46) . It is important to note that the extent of ADCC boost estimated by the cellular assays is ~100-fold, whereas the increase of affinity measured by biophysical methods is ~20-30-fold. To date, this discrepancy has not been satisfactorily addressed. The avidity effect, the dynamic behavior of IgG-Fc and the molecular environment on the cell surface could explain this discrepancy. Ongoing investigations will precisely determine the origin of these differences. Crystal structures of the IgG4-Fc portion of (a) the therapeutic antibody pembrolizumab (PDB entry code 5DK3) carrying the hinge mutation S228P and of (b) human IgG4-Fc (PDB entry code 4C54). The CH2 domain and its associated N-glycan in one of the chains of the full-length pembrolizumab show a very different conformation to that of IgG4-Fc in the crystal state. Protein is depicted in light and dark gray, and the N-glycans are both shown in green. The mutation S228P in the hinge region of pembrolizumab (not shown) abrogates Fab-arm exchange (36, 38) . The CH2-CH3 domains of the chain depicted in light gray are displayed in the same orientation in both panels.
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Effect of the N-glycan on stability
The structural behavior of IgG-Fc and its thermal stability correlate closely, since the exposure of hydrophobic residues to the solvent is one of the steps initiating protein denaturation, also manifested in a tendency to aggregate (49, 50) . In particular, the CH2 domain is an aggregation-prone region because of the large number of hydrophobic residues present there, despite being shielded by the N-glycan itself (51) . Residues Phe241, Phe243, Pro244, Val262, Val264, Val303 and Val 305 form a remarkably hydrophobic region, and not surprisingly the mutation of these residues modulates the effector function of IgG (52). Voynov et al. (53) revealed that the two aromatic residues (Phe241 and Phe243) prevent N-glycans from becoming fully exposed to the solvent. In addition, disruption of the CH-π interaction between these two phenylalanine residues and the N-glycan significantly decreased the thermal stability. These observations help to explain why deglycosylation of IgG-Fc increases the rate of heat-induced aggregation and the propensity of chemical denaturation (54) (55) (56) .
Collectively these results indicate that the presence of the N-glycan certainly contributes to reduce the dynamics of CH2, partly by its interaction with hydrophobic residues, leading to protein stabilization. Although the contribution of each individual monosaccharide remains undetermined, it is likely that modification of the composition and/or identity of the saccharides could be employed as the basis for the stabilization of IgG. Recent developments in glycoengineering capable of generating more homogeneous glycoforms will help carrying out those systematic analyses (4, 57, 58) that could ultimately be incorporated in the next generation of therapeutic antibodies (59) .
Conclusions
The approval of two glycoengineered therapeutic antibodies for the treatment of cancer was not only the culmination of a long process of discovery and optimization but also demonstrated the value of a powerful methodology that can potentially improve the therapeutic properties of numerous other antibodies. Still, we need to understand in greater detail the fundamental principles explaining the modulation by the N-glycan attached to IgG-Fc, which will require a concerted effort from structural, biophysical and computational points of view. The conclusions garnered will be essential to rationalize objectives, and to focus on the most promising strategies. We predict the number of glycoengineered antibodies employed in human therapy will increase in the coming years for the benefit of society.
